Cargando…

Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome

Allogeneic hematopoietic stem cell transplantation (A-HSCT) remains the only curative option for patients with myelodysplastic syndrome (MDS). We used the NUP98-HOXD13 (NHD13) murine model for MDS to study HSCT in a pre-clinical setting. NHD13 recipients transplanted with syngeneic bone marrow (S-HS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Yang Jo, Fry, Terry J., Aplan, Peter D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617185/ https://www.ncbi.nlm.nih.gov/pubmed/28953912 http://dx.doi.org/10.1371/journal.pone.0185219

Ejemplares similares

Appropriate pre-transplant strategy for patients with myelodysplastic syndromes receiving allogeneic haematopoietic stem cell transplantation after myeloablative conditioning
por: Wang, Hong, et al.
Publicado: (2023)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors
por: Sun, Yu‐Qian, et al.
Publicado: (2021)

Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report
por: Hamilton, Betty K, et al.
Publicado: (2013)

Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Chen, Yi-Bin, et al.
Publicado: (2009)

Second Hematopoietic Stem Cell Transplantation for Leukemia Relapsing after Myeloablative T Cell Depleted Transplants Does Not Prolong Survival
por: McIver, Zachariah A., et al.
Publicado: (2013)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation
por: Hou, Chang, et al.
Publicado: (2021)

Effects of continuous bicycle ergometer and step exercises from admission to discharge in a patient with myelodysplastic syndrome undergoing myeloablative conditioning and hematopoietic stem cell transplantation: A case report
por: Kawanishi, Makoto, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013)

Prognostic Value of Thrombocytopenia in Myelodysplastic Syndromes After Hematopoietic Stem Cell Transplantation
por: Wang, Hong, et al.
Publicado: (2022)

Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation
por: Wachter, Franziska, et al.
Publicado: (2023)

Pilot experience with opebacan/rBPI (21) in myeloablative hematopoietic cell transplantation
por: Guinan, Eva, et al.
Publicado: (2015)

Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
por: Field, Teresa, et al.
Publicado: (2010)

Thrombopoietin from hepatocytes promotes hematopoietic stem cell regeneration after myeloablation
por: Gao, Longfei, et al.
Publicado: (2021)

Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome
por: Bortnick, Rachel, et al.
Publicado: (2021)

Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation
por: Poletto, Edina, et al.
Publicado: (2022)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation
por: Vargas, Alberto Olaya, et al.
Publicado: (2013)

Upfront consolidation treatment with (131)I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma
por: Feng, Jianhua, et al.
Publicado: (2020)

Depletion of Cytotoxic T-Cells Does Not Protect NUP98-HOXD13 Mice from Myelodysplastic Syndrome but Reveals a Modest Tumor Immunosurveillance Effect
por: Gough, Sheryl M., et al.
Publicado: (2012)

Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation
por: Kook, Min-Ha, et al.
Publicado: (2014)

Pre-engraftment Syndrome in Hematopoietic Stem Cell Transplantation
por: Lee, Young-Ho, et al.
Publicado: (2008)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation
por: Kletzel, Morris
Publicado: (2013)

Patients Undergoing Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation Exhibit Depleted Vitamin C Status in Association with Febrile Neutropenia
por: Carr, Anitra C., et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection
por: Luo, Yanhui, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation for Crohn disease complicated with myelodysplastic syndrome: A case report
por: Zhang, Ying, et al.
Publicado: (2020)

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes
por: Liu, Liu, et al.
Publicado: (2021)

αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes
por: Merli, Pietro, et al.
Publicado: (2022)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease
por: Limerick, Emily, et al.
Publicado: (2022)

Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation
por: Goh, Ri-Young, et al.
Publicado: (2011)

Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease
por: Ruiz, Milton Artur, et al.
Publicado: (2017)

A gut microbiota score predicting acute graft‐versus‐host disease following myeloablative allogeneic hematopoietic stem cell transplantation
por: Han, Lijie, et al.
Publicado: (2019)

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
por: Servais, Sophie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p8s61g13idtdt6ch7vv7bss00v